Abate Ejigayehu G, Smallridge Robert C
a Division of Endocrinology, Department of Internal Medicine, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, USA.
b
Expert Rev Endocrinol Metab. 2011 Nov;6(6):793-809. doi: 10.1586/eem.11.76.
Anaplastic thyroid cancer is one of the most lethal malignancies, with dismal prognosis, resistance to multimodal treatments and a median survival of only 5-6 months. Advances in the discovery of genetic pathway aberrations involved in this aggressive disease have been made, and multiple novel therapies targeting these pathways are undergoing clinical trials. So far, there is no single effective treatment for this disease; however, multimodal therapies with a combination of surgery, radiation and chemotherapy hold some promise. We conducted a PubMed search using the words thyroid neoplasm, anaplastic thyroid carcinoma, anaplastic thyroid cancer and anaplastic thyroid neoplasm, revealing 1673 publications. We review the pathophysiology, current treatments and advances made in identifying the alterations in genetic pathways, as well as novel therapies targeting these pathways.
间变性甲状腺癌是最致命的恶性肿瘤之一，预后极差，对多模式治疗耐药，中位生存期仅5至6个月。在涉及这种侵袭性疾病的遗传途径异常的发现方面已取得进展，多种针对这些途径的新型疗法正在进行临床试验。到目前为止，针对这种疾病尚无单一有效的治疗方法；然而，手术、放疗和化疗相结合的多模式疗法有一定前景。我们使用甲状腺肿瘤、间变性甲状腺癌、间变性甲状腺癌症和间变性甲状腺肿瘤等关键词在PubMed上进行搜索，共检索到1673篇文献。我们综述了其病理生理学、当前治疗方法以及在确定遗传途径改变方面取得的进展，以及针对这些途径的新型疗法。
